GATA1 mutations in acute leukemia in children with Down syndrome

被引:16
作者
Magalhaes, IQ
Splendore, A
Emerenciano, M
Figueiredo, A
Ferrari, I
Pombo-de-Oliveira, MS
机构
[1] Inst Nacl Canc, Div Expt Med, Ctr Rio De Janeiro, BR-20231050 Rio De Janeiro, Brazil
[2] Inst Nacl Canc, Div Genet, Rio De Janeiro, Brazil
[3] Univ Brasilia, Inst Ciencias Biol, Dept Genet & Morfol, BR-70910900 Brasilia, DF, Brazil
关键词
D O I
10.1016/j.cancergencyto.2005.10.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It has been reported that somatic mutations in the X-linked GATAI gene are present in hematological clonal disorders in children with Down syndrome (DS). We analyzed retrospective samples of DS children with acute myeloid leukemia, transient leukemia (TL), and myelodysplastic syndrome (MDS) to test whether the specificity of GATAI mutations can be helpful in distinguishing these hematopoietic disorders. A total of 49 samples were subjected to GATAI mutation screening by direct sequencing and denaturing polyacrylamide gel electrophoresis (PAGE). Mutations in exon 2 of GATAI were detected in six of eight DS-AML M7 samples and in four of six DS-TL; no mutation was detected in 13 children with acute lymphoblastic leukemia (DS-ALL), 6 with DS-AML (MO, M2, and M5), 6 with DS-MDS and in 8 DS infants without hematological disorders and 2 children with AML M7 without DS. Blast cells proportion in the sample represented a critical aspect on the sensitivity of mutation detection in GATAI, and a combination of sequence analysis and PAGE is necessary to detect mutations when blast percentage is low. The absence of detected mutations in any of the DS-MDS cases raises the question whether MDS in DS children is an intermediate stage between TL and AML M7, as previously suggested. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:112 / 116
页数:5
相关论文
共 18 条
[1]  
BAIN BJ, 1999, LEUKEMIA DIAGNOSIS
[2]  
BASSAM BJ, 1991, ANAL BIOCHEM, V198, P217
[3]   CRITERIA FOR THE DIAGNOSIS OF ACUTE-LEUKEMIA OF MEGAKARYOCYTE LINEAGE (M7) - A REPORT OF THE FRENCH-AMERICAN-BRITISH COOPERATIVE GROUP [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
ANNALS OF INTERNAL MEDICINE, 1985, 103 (03) :460-462
[4]   ALTERNATIVE TRANSLATION INITIATION SITE USAGE RESULTS IN 2 FUNCTIONALLY DISTINCT FORMS OF THE GATA-1 TRANSCRIPTION FACTOR [J].
CALLIGARIS, R ;
BOTTARDI, S ;
COGOI, S ;
APEZTEGUIA, I ;
SANTORO, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (25) :11598-11602
[5]   GATA1 mutations in Down syndrome:: Implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia [J].
Crispino, JD .
PEDIATRIC BLOOD & CANCER, 2005, 44 (01) :40-44
[6]  
DENDUNNEN J, 2005, NOMENCLATURE DESCRIP
[7]  
Down JL., 1866, CLIN LECT REPORTS ME, V3, P259, DOI DOI 10.1038/HDY.1966.69
[8]   DOWNS-SYNDROME AND LEUKEMIA - EPIDEMIOLOGY, GENETICS, CYTOGENETICS AND MECHANISMS OF LEUKEMOGENESIS [J].
FONG, C ;
BRODEUR, GM .
CANCER GENETICS AND CYTOGENETICS, 1987, 28 (01) :55-76
[9]  
Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
[10]   A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases [J].
Hasle, H ;
Niemeyer, CM ;
Chessells, JM ;
Baumann, I ;
Bennett, JM ;
Kerndrup, G ;
Head, DR .
LEUKEMIA, 2003, 17 (02) :277-282